Priced out

AFteR a fortune has been spent researching and developing ocrelizumab, the first drug to effectively treat primary progressive multiple sclerosis, it has been deemed too expensive by NIce to be used to treat NHS patients.

What is the point in this kind of research if it has no outcome? It’s a waste of money, time and effort for the scientists.

How devastating for anyone with this illness to know there is a treatment that can give them back their quality of life, but they can’t have it. STEPHANIE ROWE,

Saltash, Cornwall.